Q1 2025 Holdings
Filed 2025-05-15 | 43 holdings | $581.7M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc.(CGEM) | Common | 230031106 | $57.9M | 7,648,268 | 10.0% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $33.3M | 100,415 | 5.7% |
| Zai Lab Ltd(ZLAB) | ADR | 98887Q104 | $30.1M | 833,659 | 5.2% |
| Edgewise Therapeutics Inc(EWTX) | Common | 28036F105 | $24.3M | 1,105,444 | 4.2% |
| Lantheus Holdings Inc(LNTH) | Common | 516544103 | $22.7M | 232,387 | 3.9% |
| PTC Therapeutics Inc(PTCT) | Common | 69366J200 | $22.4M | 439,977 | 3.9% |
| Natera Inc(NTRA) | Common | 632307104 | $22.2M | 157,047 | 3.8% |
| Trevi Therapeutics Inc(TRVI) | Common | 89532M101 | $21.6M | 3,428,366 | 3.7% |
| Crinetics Pharmaceuticals Inc.(CRNX) | Common | 22663K107 | $21.2M | 631,964 | 3.6% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $21.1M | 714,224 | 3.6% |
| Guardant Health Inc(GH) | Common | 40131M109 | $18.9M | 442,656 | 3.2% |
| United Therapeutics Corp.(UTHR) | Common | 91307C102 | $18.2M | 58,907 | 3.1% |
| ARS Pharmaceuticals Inc(SPRY) | Common | 82835W108 | $16.5M | 1,313,104 | 2.8% |
| Compass Therapeutics, Inc.(CMPX) | Common | 20454B104 | $16.0M | 8,442,783 | 2.8% |
| Janux Therapeutics Inc(JANX) | Common | 47103J105 | $15.3M | 567,193 | 2.6% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $14.4M | 398,445 | 2.5% |
| Moonlake Immunotherapeutics(MLTX) | Class A Ord | 61559X104 | $12.3M | 316,049 | 2.1% |
| Wave Life Sciences PTE LTD(WVE) | Common | Y95308105 | $12.2M | 1,509,580 | 2.1% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $11.2M | 317,083 | 1.9% |
| Alkermes Plc(ALKS) | Common | G01767105 | $11.1M | 337,603 | 1.9% |
| Olema Pharmaceuticals, Inc.(OLMA) | Common | 68062P106 | $11.0M | 2,930,446 | 1.9% |
| Rocket Pharmaceuticals, Inc.(RCKT) | Common | 77313F106 | $10.8M | 1,618,265 | 1.9% |
| iTeos Therapeutics, Inc.(5E7) | Common | 46565G104 | $10.4M | 1,745,943 | 1.8% |
| Cartesian Therapeutics Inc(RNAC) | Common | 816212302 | $10.4M | 790,779 | 1.8% |
| Twist Bioscience Corp(TWST) | Common | 90184D100 | $10.3M | 261,215 | 1.8% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $10.2M | 303,398 | 1.7% |
| Vera Therapeutics Inc.(VERA) | Class A Ord | 92337R101 | $10.0M | 415,719 | 1.7% |
| Replimune Group Inc(REPL) | Common | 76029N106 | $9.6M | 987,036 | 1.7% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $9.0M | 2,708,582 | 1.6% |
| Context Therapeutics Inc(CNTX) | Common | 21077P108 | $9.0M | 14,705,882 | 1.5% |
| MBX Biosciences Inc(MBX) | Common | 55287L101 | $8.4M | 1,132,950 | 1.4% |
| Nuvation Bio Inc(NUVB) | Common | 67080N101 | $8.2M | 4,652,243 | 1.4% |
| Oric Pharmaceuticals Inc(ORIC) | Common | 68622P109 | $7.8M | 1,399,514 | 1.3% |
| Ideaya Biosciences, Inc.(IDYA) | Common | 45166A102 | $7.0M | 430,161 | 1.2% |
| Solid Biosciences Inc(SLDB) | Common | 83422E204 | $6.1M | 1,642,356 | 1.0% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $6.0M | 2,295,924 | 1.0% |
| Stoke Therapeutics Inc(STOK) | Common | 86150R107 | $4.6M | 693,988 | 0.8% |
| Veru Inc.(VERUEUR) | Common | 92536C103 | $3.2M | 6,592,727 | 0.6% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $2.3M | 2,408,810 | 0.4% |
| Design Therapeutics Inc(DSGN) | Common | 25056L103 | $2.2M | 562,943 | 0.4% |
| Adaptimmune Therapeutics plc(ADAPY) | Sponsored ADR | 00653A107 | $964.2K | 4,894,344 | 0.2% |
| Repare Therapeutics, Inc.(RPTX) | Common | 760273102 | $808.4K | 819,924 | 0.1% |
| ALX Oncology Holdings Inc.(ALXO) | Common | 00166B105 | $342.7K | 550,000 | 0.1% |